These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37023853)

  • 1. Development and Validation of Physiologically Based Pharmacokinetic Model of Levetiracetam to Predict Exposure and Dose Optimization in Pediatrics.
    Shao W; Shen C; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
    J Pharm Sci; 2023 Oct; 112(10):2667-2675. PubMed ID: 37023853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.
    Maglalang PD; Sinha J; Zimmerman K; McCann S; Edginton A; Hornik CP; Hornik CD; Muller WJ; Al-Uzri A; Meyer M; Chen JY; Anand R; Perrin EM; Gonzalez D;
    Clin Pharmacokinet; 2024 Jun; 63(6):885-899. PubMed ID: 38814425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brivaracetam exposure-response predictions in pediatric patients from age 1 month: Extrapolation of levetiracetam adult-pediatric scaling to brivaracetam.
    Schoemaker R; Krauwinkel W; Elshoff JP; Stockis A
    Epilepsy Res; 2024 May; 202():107332. PubMed ID: 38518434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
    Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
    Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
    Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
    Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically-based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents.
    Sinha J; Karatza E; Gonzalez D
    CPT Pharmacometrics Syst Pharmacol; 2022 Feb; 11(2):225-239. PubMed ID: 34816634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children With Epilepsy.
    Kim MJ; Yum MS; Yeh HR; Ko TS; Lim HS
    J Clin Pharmacol; 2018 Dec; 58(12):1586-1596. PubMed ID: 30052270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations.
    Shen C; Shao W; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
    CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):1001-1015. PubMed ID: 37170680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
    Yun YE; Edginton AN
    J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling.
    Guan R; Li X; Ma G
    Front Pharmacol; 2023; 14():1326373. PubMed ID: 38089044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model.
    Rashid M; Sarfraz M; Arafat M; Hussain A; Abbas N; Sadiq MW; Rasool MF; Bukhari NI
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):56. PubMed ID: 32727574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Develop adult extrapolation to pediatrics and pediatric dose optimization based on the physiological pharmacokinetic model of azithromycin.
    Liang L; Li W; Zhang Z; Li D; Pu S; Xiang R; Zhai F
    Biopharm Drug Dispos; 2023 Jun; 44(3):245-258. PubMed ID: 37080927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically-Based Pharmacokinetic Modeling and Dosing Optimization of Cefotaxime in Preterm and Term Neonates.
    Li Q; Guan Y; Xia C; Wu L; Zhang H; Wang Y
    J Pharm Sci; 2024 Aug; 113(8):2605-2615. PubMed ID: 38460573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.
    Hornik CP; Wu H; Edginton AN; Watt K; Cohen-Wolkowiez M; Gonzalez D
    Clin Pharmacokinet; 2017 Nov; 56(11):1343-1353. PubMed ID: 28290120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy.
    Chen J; You X; Wu W; Guo G; Lin R; Ke M; Huang P; Lin C
    Eur J Pharm Sci; 2023 Feb; 181():106349. PubMed ID: 36496167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically based pharmacokinetic models for predicting lamotrigine exposure and dose optimization in pediatric patients receiving combination therapy with carbamazepine or valproic acid.
    Liu Z; Shao W; Wang X; Geng K; Wang W; Li Y; Chen Y; Xie H
    Pharmacotherapy; 2024 Sep; 44(9):711-721. PubMed ID: 39206763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of a Pragmatic PBPK Modeling Approach: Towards Model-Informed Dosing in Pediatric Clinical Care.
    van der Heijden JEM; Freriksen JJM; de Hoop-Sommen MA; van Bussel LPM; Driessen SHP; Orlebeke AEM; Verscheijden LFM; Greupink R; de Wildt SN
    Clin Pharmacokinet; 2022 Dec; 61(12):1705-1717. PubMed ID: 36369327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
    Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
    Khalil F; Läer S
    AAPS J; 2014 Mar; 16(2):226-39. PubMed ID: 24399240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.